- When someone needs a blood stem cell transplant, the hunt is on for a matching donor. What makes a donor a ‘match’ is largely down to molecules called HLA. But HLA has an…
- Over half of all stem cell transplant patients will experience some form of graft versus host disease (GvHD), a condition where donated cells start mistakenly attacking the…
- Against daily news articles on COVID-19’s impact and possible new treatments or vaccines, it can be very hard to get a clear…
- In this blog, our Science Communications Manager, Jonathan Kay, looks at a recent study that highlights the potential benefits of selecting a cord blood transplant over a matched…
- For over 45 years Anthony Nolan has recruited potential stem cell donors to their register – people who are willing to donate their cells to someone in need of a lifesaving stem…
- Umbilical cord blood (UCB) has huge potential, not only as a successful alternative source of hematopoietic blood cells for transplant/clinical application, but in research and…
- Ensuring care has the patient at the centre is a key aim for the NHS and something we’re particularly interested in at Anthony Nolan. Our post-transplant care pathway sets out one…
- Here, Anthony Nolan’s Chief Executive, Henny Braund, gives an overview of current and emerging treatments for blood cancer and the developments needed to give patients the best…
- Through the Anthony Nolan Cell & Gene Therapy Service’s provision of cellular material to cell and gene therapy researchers, we are familiar with industry standards and…
- Key highlights from the Anthony Nolan Research Institute Symposium In early March, we hosted a Symposium on the contributions by the Anthony Nolan Research Institute (ANRI…
This page has been auto translated by Google Translate. Confirm any health information with your own medical team before acting upon it. All printed materials and PDFs are available in English only.